{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.3616.200.110.102.4014","meta":{"versionId":"5","lastUpdated":"2020-08-18T10:21:27.000-04:00"},"text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\">\n      <h2>COVID19 ICD10PCS Value Set for Administration of Immunosuppressive Therapy</h2>\n      <p>This value set includes codes from the following code systems:</p>\n      <ul>\n        <li>Include these codes as defined in \n          <code>http://www.icd10data.com/icd10pcs</code>\n          <table class=\"none\">\n            <tr>\n              <td>\n                <b>Code</b>\n              </td>\n              <td>\n                <b>Display</b>\n              </td>\n            </tr>\n            <tr>\n              <td>3E030WL</td>\n              <td>Introduction of Immunosuppressive into Peripheral Vein, Open</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E033WL</td>\n              <td>Introduction of Immunosuppressive into Peripheral Vein, Percutaneous</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E040WL</td>\n              <td>Introduction of Immunosuppressive into Central Vein, Open</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E043WL</td>\n              <td>Introduction of Immunosuppressive into Central Vein, Percutaneous</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E050WL</td>\n              <td>Introduction of Immunosuppressive into Peripheral Artery, Open</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E053WL</td>\n              <td>Introduction of Immunosuppressive into Peripheral Artery, Percutaneous</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E060WL</td>\n              <td>Introduction of Immunosuppressive into Central Artery, Open</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>3E063WL</td>\n              <td>Introduction of Immunosuppressive into Central Artery, Percutaneous</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>XW03351</td>\n              <td>Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>XW04351</td>\n              <td>Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1</td>\n              <td/>\n            </tr>\n          </table>\n        </li>\n      </ul>\n    </div>"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.4014","version":"20200722","name":"COVID19 ICD10PCS Value Set for Administration of Immunosuppressive Therapy","status":"active","date":"2020-07-22T01:00:33-04:00","publisher":"Clinical Architecture","compose":{"include":[{"system":"http://www.icd10data.com/icd10pcs","concept":[{"code":"3E030WL","display":"Introduction of Immunosuppressive into Peripheral Vein, Open"},{"code":"3E033WL","display":"Introduction of Immunosuppressive into Peripheral Vein, Percutaneous"},{"code":"3E040WL","display":"Introduction of Immunosuppressive into Central Vein, Open"},{"code":"3E043WL","display":"Introduction of Immunosuppressive into Central Vein, Percutaneous"},{"code":"3E050WL","display":"Introduction of Immunosuppressive into Peripheral Artery, Open"},{"code":"3E053WL","display":"Introduction of Immunosuppressive into Peripheral Artery, Percutaneous"},{"code":"3E060WL","display":"Introduction of Immunosuppressive into Central Artery, Open"},{"code":"3E063WL","display":"Introduction of Immunosuppressive into Central Artery, Percutaneous"},{"code":"XW03351","display":"Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1"},{"code":"XW04351","display":"Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1"}]}]}}